Abstracts Archive - Page 988 of 2425 - ACR Meeting Abstracts

Abstract Number: 505 • 2019 ACR/ARP Annual Meeting
Low-grade Total Rheumatoid Arthritis MRI Scoring System Can Predict Successful Half-dose Reduction of MTX in Patients with RA in Clinical Remission
Takeshi Suzuki¹, Marina Uchida ², Shoshi Shinagawa ², Machiko Mizushima ³, Takayasu Ando ³, Yutaka Gotou ³, Tomohiko Shibata ² and Kimito Kawahata ⁴, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Division of Rheumatology, Department of Internal Medicine, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Yokohama, Kanagawa, Japan, ³Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, ⁴Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan
Background/Purpose: It has been recommended that tapering csDMARDs should be considered if a patient is in persistent remission. However, methods for tapering csDMARDs, including MTX,…
Abstract Number: 506 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results
Bernard Combe¹, Alan Kivitz ², Yoshiya Tanaka ³, Désirée van der Heijde ⁴, Franziska Matzkies ⁵, Beatrix Bartok ⁵, Lei Ye ⁵, Ying Guo ⁵, Chantal Tasset ⁶, John Sundy ⁵, Neelufar Mozaffarian ⁵, Robert B.M. Landewé ⁷, Sang-Cheol Bae ⁸, Edward Keystone ⁹ and Peter Nash ¹⁰, ¹CHU Montpellier, Montpellier University, Montpellier, France, ²Altoona Center for Clinical Research, Duncansville, PA, ³University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos NV, Mechelen, Belgium, ⁷Amsterdam University Medical Center, Amsterdam, Netherlands, ⁸Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰University of Queensland, Brisbane, Queensland, Australia
Background/Purpose: Filgotinib (FIL) is an orally administered, potent and selective inhibitor of Janus kinase 1 (JAK1) that has shown good efficacy and was well tolerated…
Abstract Number: 507 • 2019 ACR/ARP Annual Meeting
Inhibition of Joint Destruction in Patients with Rheumatoid Arthritis Treated with Peficitinib in Combination with Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial in Japan
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Mitsuhiro Rokuda ³, Hiroyuki Izutsu ³, Yuichiro Kaneko ³, Musashi Fukuda ³, Daisuke Kato ³ and Désirée van der Heijde ⁴, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Astellas Pharma, Inc., Tokyo, Japan, ⁴Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Peficitinib (PEF), a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in Phase 3 studies of patients with RA (NCT02305849).1 We report the…
Abstract Number: 508 • 2019 ACR/ARP Annual Meeting
Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Sakae Tanaka ³, Atsushi Kawakami ⁴, Yeong-Wook Song ⁵, Yi-Hsing Chen ⁶, Mitsuhiro Rokuda ⁷, Hiroyuki Izutsu ⁷, Satoshi Ushijima ⁷, Yuichiro Kaneko ⁷, Yoshihiro Nakashima ⁷, Teruaki Shiomi ⁷ and Emi Yamada ⁷, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³University of Tokyo, Tokyo, Japan, ⁴Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Seoul National University Hospital, Seoul, Republic of Korea, ⁶Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁷Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, demonstrated efficacy and an acceptable safety profile in a Phase 2b study (RAJ1 study, NCT01649999) and…
Abstract Number: 509 • 2019 ACR/ARP Annual Meeting
Safety Profile of Upadacitinib in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program
Stanley Cohen¹, Ronald van Vollenhoven ², Kevin Winthrop ³, Cristiano A. Zerbini ⁴, Yoshiya Tanaka ⁵, Louis Bessette ⁶, Ying Zhang ⁷, Nasser Khan ⁸, Barbara Hendrickson ⁷, Jose Jeffrey Enejosa ⁷ and Gerd Burmester ⁹, ¹Metroplex Clinical Research Center, Dallas, TX, ²Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ³Oregon Health and Science University, Portland, OR, ⁴Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁵University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁶Laval University, Quebec City, QC, Canada, ⁷AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁸Abbvie Inc, North Chicago, IL, ⁹Charité—University Medicine Berlin, Berlin, Germany
Background/Purpose: Upadacitinib (UPA), an oral JAK1-selective inhibitor, was evaluated in a comprehensive clinical program of 5 pivotal Phase 3 randomized-controlled trials (RCTs) across the full…
Abstract Number: 510 • 2019 ACR/ARP Annual Meeting
Treatment with Upadacitinib Is Associated with Improvements in Reverse Cholesterol Transport in Patients with Rheumatoid Arthritis: Correlation with Changes in Inflammation and HDL Levels
Christina Charles-Schoeman¹, Thierry Sornasse ² and Jeremy Sokolove ², ¹University of California, Los Angeles, CA, ²AbbVie Immunology Clinical Development, Redwood City
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory condition associated with increased rates of atherosclerotic progression via pathogenic remodeling of high-density lipoprotein (HDL)-associated proteins, resulting…
Abstract Number: 511 • 2019 ACR/ARP Annual Meeting
A Comparative Analysis of Upadacitinib Monotherapy and Upadacitinib Combination Therapy for the Treatment of Rheumatoid Arthritis from Two Phase 3 Trials
Maya H. Buch¹, Alvin F. Wells ², Andrea Rubbert-Roth ³, Manish Jain ⁴, Casey Schlacher ⁵, Heidi Camp ⁵, Yihan Li ⁵, Yanna Song ⁶ and Peter Nash ⁷, ¹University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ²Rheumatology and Immunotherapy Center, Franklin, ³Kantonsspital St. Gallen, St Gallen, Switzerland, ⁴Rheumatology, Great Lakes Clinical Trials, Great Lakes, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁷University of Queensland, Brisbane, Queensland, Australia
Background/Purpose: Upadacitinib (UPA), a selective JAK1 inhibitor, has demonstrated efficacy and safety in patients with rheumatoid arthritis (RA) as monotherapy and in combination with conventional…
Abstract Number: 512 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Upadacitinib Monotherapy in MTX-naïve Patients with Early Active RA Receiving Treatment Within 3 Months of Diagnosis: A Post-hoc Analysis of the SELECT-EARLY
Meliha Kapetanovic¹, Maria Andersson ², Alan Friedman ³, Tim Shaw ³, Yanna Song ⁴, Daniel Aletaha ⁵, Maya H. Buch ⁶, Ulf Müller-Ladner ⁷ and Janet Pope ⁸, ¹Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, ²Abbvie AB, Solna, Sweden, ³AbbVie Inc., North Chicago, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁵Medical University of Vienna, Vienna, Austria, ⁶University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁷Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, Gießen, Hessen, Germany, ⁸Western University, London, ON, Canada
Background/Purpose: Early treatment of RA within the therapeutic window (0-3 months from symptom onset), has been associated with improved clinical outcomes and physical function. However,…
Abstract Number: 513 • 2019 ACR/ARP Annual Meeting
Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 Weeks
Josef Smolen¹, Paul Emery ², William Rigby ³, Yoshiya Tanaka ⁴, Juan Ignacio Vargas ⁵, Nemanja Damjanov ⁶, Manish Jain ⁷, Yunxia Sui ⁸, Jose Jeffrey Enejosa ⁹, Aileen Pangan ¹⁰, Heidi Camp ⁹ and Stanley Cohen ¹¹, ¹Medical University of Vienna, Vienna, Austria, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ³Dartmouth-Hitchcock Medical Center, Lebanon, ⁴University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁵Quantum Research, Puerto Varas, Chile, ⁶Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, Belgrade, Serbia, ⁷Rheumatology, Great Lakes Clinical Trials, Great Lakes, ⁸AbbVie Inc., Chicago, ⁹AbbVie Inc., North Chicago, IL, ¹⁰AbbVie Inc., North Chicago, ¹¹Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In the SELECT-MONOTHERAPY trial, upadacitinib (UPA), an oral JAK1-selective inhibitor, showed efficacy when used as monotherapy over 14 weeks (wks) in rheumatoid arthritis (RA)…
Abstract Number: 514 • 2019 ACR/ARP Annual Meeting
A Pooled Analysis of 1-year Clinical Outcomes Among 6-month Responders and Non-responders from Three Randomized Controlled Studies of TNF Inhibitor Biosimilars in Patients with Rheumatoid Arthritis
Josef Smolen¹, Michael Weinblatt ², Paul Emery ³, Jung Yoon Choe ⁴, Jonathan Kay ⁵, Jieun Lee ⁶, Gihyun Myung ⁶, Hyoryeong Seo ⁶ and Jeehoon Ghil ⁶, ¹Medical University of Vienna, Vienna, Austria, ²Brigham and Women's Hospital, Boston, MA, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁴Division of Rheumatology, Daegu Catholic University Medical Center, Daegu, Republic of Korea, ⁵UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁶Samsung Bioepis Co., Ltd., Incheon, Republic of Korea
Background/Purpose: SB4, SB2, and SB5 are biosimilars of etanercept, infliximab, and adalimumab. Phase III randomized, double-blind studies were conducted to compare efficacy and safety between…
Abstract Number: 515 • 2019 ACR/ARP Annual Meeting
Clinical Responses in Patients with Inadequate Response to bDMARDs upon Treatment with Upadacitinib
Michael Weinblatt¹, Glen Thomson ², Kun Chen ³, Sebastian Meerwein ⁴, Casey Schlacher ⁵ and John Cush ⁶, ¹Brigham and Women's Hospital, Boston, MA, USA, Boston, MA, ²CIADS Research, Winnipeg, Canada, ³AbbVie Inc., North Chicago, ⁴AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁵AbbVie Inc., North Chicago, IL, ⁶5Baylor University Medical Center, Dallas
Background/Purpose: Upadacitinib (UPA), a JAK1-selective inhibitor, demonstrated efficacy in the SELECT-BEYOND study in patients (pts) with moderate to severe rheumatoid arthritis (RA) on a stable…
Abstract Number: 516 • 2019 ACR/ARP Annual Meeting
Impact of Baseline Demographics and Disease Activity on Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib
Michael Weinblatt¹, Eduardo Mysler ², Andrew Östör ³, Aaron Broadwell ⁴, Slawomir Jeka ⁵, Kendall Dunlap ⁶, Jessica Suboticki ⁶, Jose Jeffrey Enejosa ⁶, Barbara Hendrickson ⁶, Sheng Zhong ⁶, Katya Cherny ⁶ and Grace Wright ⁷, ¹Brigham and Women's Hospital, Boston, MA, USA, Boston, MA, ²Organización Medica de Investigación, Buenos Aires, Argentina, Buenos Aires, Argentina, ³Cabrini Medical Centre, Monash University, Malvern, Australia, Malvern, Australia, ⁴Rheumatology and Osteoporosis Specialists, Shreveport, LA, USA, Shreveport, LA, ⁵University Hospital Bydgoszcz no 2, CM UMK, Bydgoszcz, Poland, ⁶AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁷New York University Langone Medical Center, New York, NY, USA, New York
Background/Purpose: Upadacitinib (UPA), an oral selective JAK1 inhibitor, has demonstrated favorable efficacy and acceptable safety in five Phase 3 global studies in patients with moderately…
Abstract Number: 517 • 2019 ACR/ARP Annual Meeting
A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs
Mark Genovese¹, Kurt de Vlam ², Jacques-Eric Gottenberg ³, Beatrix Bartok ⁴, Iyabode Tiamiyu ⁴, Ying Guo ⁴, Chantal Tasset ⁵, John Sundy ⁴, David Walker ⁶, Tsutomu Takeuchi ⁷ and Kenneth Kalunian ⁸, ¹Stanford University, Stanford, CA, ²Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Northumbria Healthcare, Northumbria, United Kingdom, ⁷Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁸Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA
Background/Purpose: There is an unmet medical need to treat RA in patients who have failed prior biologic DMARD treatments (biologic DMARD inadequate response; bDMARD-IR), some…
Abstract Number: 518 • 2019 ACR/ARP Annual Meeting
Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks
Mark Genovese¹, Bernard Combe ², Stephen Hall ³, Andrea Rubbert-Roth ⁴, Sheng Zhong ⁵, Sebastian Meerwein ⁶, Aileen Pangan ⁷ and Roy Fleischmann ⁸, ¹Stanford University, Stanford, CA, ²CHU Montpellier, Montpellier University, Montpellier, France, ³Monash University and Emeritus Research, Melbourne, Australia, ⁴Kantonsspital St. Gallen, St Gallen, Switzerland, ⁵AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁶AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁷AbbVie Inc., North Chicago, ⁸Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: In patients (pts) with active rheumatoid arthritis (RA) and inadequate response or intolerance to bDMARDs, treatment with upadacitinib (UPA), a JAK1-selective inhibitor resulted in…
Abstract Number: 519 • 2019 ACR/ARP Annual Meeting
Efficacy of Biosimilar Candidate ABP 710 in a Phase 3 Study in Subjects with Moderate to Severe RA: Additional Analysis Focusing on the ACR Individual Components
Mark Genovese¹, Juan Sanchez-Burson ², Éva Balázs ³, Andrea Everding ⁴, MyungShin Oh ⁵, Gary Fanjiang ⁵ and Stanley Cohen ⁶, ¹Stanford University, Stanford, CA, ²Hospital Infanta Luisa, Sevilla, Spain, ³Dr. Bugyi István Hospital, Szentes, Hungary, ⁴HRF Hamburger Rheuma Forschungszentrum, Hamburg, Germany, ⁵Amgen, Thousand Oaks, CA, ⁶Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: ABP 710 is being developed as a biosimilar to infliximab. Both ABP 710 and infliximab reference product (RP) inhibit tumor necrosis factor-alpha. Following demonstration…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].